and glibenclamide treatment vs insulin and placebo was carried out in 20 insulin-dependent diabetics. Nine patients were C-peptide secretors and all increased their C-peptide output during a 50 g OGTT at the end of the insulin and glibenclamide treatment period by a mean of 47%. At the same time their mean daily blood glucose fell from 8.4 \m=+-\1.7 to 7.4 \m=+-\1.5 mmol/l and their HbA1 from 8.1 \m=+-\0.5to 7.5 \m=+-\0.9%(mean \ m=+-\sd). There was no change in any of the measurements of diabetic control in C-peptide non-secretors and no evidence for any extrapancreatic effects of glibenclamide in this group of patients. Combined insulin and glibenclamide treatment may produce a useful improvement of diabetic control in insulin-dependent diabetics who still secrete some endogenous insulin, although further studies are required.
The retention of endogenous insulin secretion by insulin-dependent diabetics has been considered to be important for the maintenance of stable control of their blood glucose and in preventing long-term diabetic complications (Binder & Faber 1978; Lutterman et al. 1981 ). However, Madsbad (1983) has recently suggested that retention of consider¬ able ß cell function is necessary if endogenous insulin secretion is to be useful. It has previously been demonstrated that glibenclamide can increase endogenous insulin secretion, measured by in¬ creased plasma and urine C-peptide concentrations when given in addition to the insulin treatment regimen of insulin-dependent diabetics who still secrete some insulin (Burke & Sherriff 1980) (Kuzuya et al. 1977) , by the method of Heding (1975) C-peptide ratio were also significantly different in Group A subjects with an increase in C-peptide (P<0.001) and a reduced ratio (P < 0.001).
Discussion secretion reflected by a fasting plasma C-peptide concentration above 0.07 nmol/1 (Hendriksen et al. 1977; Garcia-Webb et al. 1982 ) is a useful metabolic advantage. However, he concedes that a poststimulatory C-peptide concentration above 0.3 nmol/I is likely to be associated with better metabolic control. Of the 9 patients of our group A classified as C-peptide secretors, 6 had post-stimu¬ latory values above 0.3 nmol/1, 1 just below (0.27 nmol/1) whilst 2 others (0.18 and 0.2 nmol/1) were lower. The chosen classification of our pa¬ tients into C-peptide secretors and non-secretors seems justified by the statistical analysis of the various measurments of diabetic control during the placebo period. This analysis shows that Group A subjects show no difference from Group subjects except in two respects. These are significantly higher C-peptide concentrations and lower fasting blood glucose values in Group A subjects. Taken together this seems reasonable evidence for separa¬ ting Group A from Group subjects on the basis of their residual endogenous insulin secretion. The 9 patients of Group A showed an increased secre¬ tion of C-peptide after 3 months combined treat¬ ment with insulin and glibenclamide suggesting that the increased insulin secretion in such patients persists longer than the 1 month of our previous study (Burke & Sherriff 1980 (Reaven & Dray 1967) .
The reported extra-pancreatic effects include an increase in insulin sensitivity (Lebovitz et al. 1977) possibly due to an increase in the number of insulin receptors (Feinglos & Lebovitz 1978 
